Clinical Trials Browser

Phase 3 × Lymphoma × Lenalidomide × Clear all

NCT06191744 2026-05-06

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06084936 2026-05-04

GLOBRYTE

Phase 3 Recruiting

Lymphoma

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01239797 2022-06-01

ELOQUENT - 2

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01122472 2021-07-26

REMARC

Phase 3 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01098656 2018-07-09

Lenalidomide Maintenance Post-debulking in Advanced CTCL

Phase 3 Terminated

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous